Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Medicine, General & Internal
A. Jayk Bernal et al.
Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Jennifer Hammond et al.
Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
R. L. Gottlieb et al.
Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
William A. Fischer et al.
Summary: In a clinical trial, the safety, tolerability, and antiviral efficacy of molnupiravir were evaluated in unvaccinated individuals with confirmed SARS-CoV-2 infection. The study found that participants receiving high-dose molnupiravir had a shorter time to viral RNA clearance and a lower detection rate of infectious virus. Molnupiravir was well tolerated across all doses.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Letter
Cell Biology
Yao Zhao et al.
Article
Biochemistry & Molecular Biology
Juliana C. Ferreira et al.
Summary: This study investigates the impact of specific amino acid substitutions at key sites of the dimer interface of 3CLpro on its catalytic activity. The results provide insights on potential allosteric sites that may be targeted for the development of antiviral compounds.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2022)
Article
Chemistry, Medicinal
Yuto Unoh et al.
Summary: S-217622 is the first oral noncovalent, nonpeptidic SARS-CoV-2 3CL protease inhibitor clinical candidate, which could be a potential oral agent for treating COVID-19.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
News Item
Infectious Diseases
Sharmila Devi
LANCET INFECTIOUS DISEASES
(2022)
Article
Cell Biology
Laura J. Stevens et al.
Summary: This study identified mutations in the nonstructural protein 12 RNA-dependent RNA polymerase of the SARS-CoV-2 virus that confer resistance to the antiviral drug remdesivir. These mutations result in decreased preference for the drug as a substrate and can be transferred to other betacoronaviruses, causing replication defects and up to 38-fold resistance. The findings highlight the importance of further research to understand and prevent the emergence of remdesivir resistance mutations in clinical settings.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Hengrui Liu et al.
Summary: The authors have described small molecule inhibitors of the SARS-CoV-2 3CL protease for potential treatment of COVID-19. These inhibitors have shown promising antiviral activity and could serve as valuable tools in controlling the ongoing pandemic.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Shiv Gandhi et al.
Summary: This article reports a case of remdesivir resistance mutation in an immunocompromised patient with SARS-CoV-2 infection. The patient developed viral shedding recurrence and whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase. In vitro experiments showed that this mutation increased remdesivir resistance but had a fitness cost in the absence of remdesivir. The patient achieved sustained clinical and virologic response with casirivimab-imdevimab treatment.
NATURE COMMUNICATIONS
(2022)
Article
Microbiology
Sho Iketani et al.
Summary: This study systematically investigates the mutations of SARS-CoV-2 3CL protease using a yeast-based mutational scanning approach, and validates some of the results in authentic viruses. The research reveals the high malleability of 3CL protease, while identifying immutable residues that may serve as targets for future drug inhibitors.
CELL HOST & MICROBE
(2022)
Article
Chemistry, Medicinal
Kai S. Yang et al.
Summary: The approval of the combination therapy PAXLOVID has boosted morale in fighting the COVID-19 pandemic. The analysis in the article discusses possible mutations in the M-Pro that could lead to acquired viral resistance to nirmatrelvir and its implications for fighting future drug-resistant viral variants.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Multidisciplinary Sciences
Qian Wang et al.
Summary: SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have become dominant in the United States and South Africa, raising concerns about their ability to evade neutralizing antibodies and compromise the efficacy of COVID-19 vaccines and therapeutic monoclonals. A systematic antigenic analysis reveals that BA.2.12.1 and BA.4/5 have different levels of resistance to antibodies, with BA.2.12.1 being modestly resistant and BA.4/5 being substantially resistant. Certain mutations in the spike protein facilitate antibody escape, but compromise the spike affinity for the viral receptor. Only bebtelovimab retains full potency against both subvariants.
Article
Medicine, General & Internal
Heba N. Altarawneh et al.
Summary: An analysis of data from Qatar showed that previous infection, vaccination, and hybrid immunity all demonstrated effectiveness in protecting against symptomatic Covid-19 caused by the BA.1 and BA.2 sublineages of the Omicron variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Ala M. Shaqra et al.
Summary: The study determined the crystal structures of SARS-CoV-2 main protease (Mpro) bound to substrate peptides, defining the substrate envelope and identifying sites susceptible to drug resistance. These findings provide insights for developing robust inhibitors against SARS-CoV-2 and preventing drug resistance.
NATURE COMMUNICATIONS
(2022)
Article
Microbiology
Hiroshi Mukae et al.
Summary: This study evaluated the efficacy and safety of ensitrelvir in Japanese patients with COVID-19. The results demonstrated rapid viral clearance and good tolerability with ensitrelvir treatment.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Aditya K. Padhi et al.
Summary: This study identified hotspot residues and signatures of adaptation in Mpro through a unique high-throughput protein design technique, which is crucial for understanding viral adaptation, robust antiviral design, and surveillance of evolving Mpro variations.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Sho Iketani et al.
Summary: The identification of the Omicron variant of SARS-CoV-2 in Botswana in November 2021 sparked concern due to the spike protein alterations that could potentially evade antibodies. Further studies showed that the Omicron sublineages, BA.1+R346K and BA.2, are antigenically similar to the wild-type virus and pose similar risks to the effectiveness of current vaccines. BA.2 also demonstrated resistance to many neutralizing monoclonal antibodies, highlighting the challenges in developing effective therapeutic options.
Letter
Cell Biology
Michael Dominic Sacco et al.
Article
Biochemical Research Methods
Susana Posada-Cespedes et al.
Summary: V-pipe is a bioinformatics pipeline designed to support viral high-throughput sequencing studies, incorporating various statistical models and computational tools. It allows for quality control, read mapping, low-frequency mutation calling, and inference of viral haplotypes. Through comparative evaluations of different pipeline configurations, the impact of different read aligners and variant callers on calling single-nucleotide variants in intra-host virus populations is demonstrated.
Article
Medicine, General & Internal
D. M. Weinreich et al.
Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Peter Chen et al.
Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Microbiology
Wendy P. Painter et al.
Summary: Molnupiravir showed rapid appearance and dose-proportional increase in plasma, with good tolerability in healthy volunteers. The study evaluated single and multiple doses of molnupiravir and the impact of food on pharmacokinetics in subjects, showing no accumulation following multiple doses and a decrease in absorption rate when administered with food, but no decrease in overall exposure.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Medicine, General & Internal
Anil Gupta et al.
Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Multidisciplinary Sciences
Dafydd R. Owen et al.
Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.
Article
Biology
Albert Tian Chen et al.
Summary: COVID-19 CG is an open resource for tracking SARS-CoV-2 single-nucleotide variations, lineages, and clades using the GISAID database. Users can query SNVs across different regions, mutations impacting diagnostic sensitivity, and the emergence of dominant lineages. The platform will be upgraded with new features to rapidly pinpoint mutations as the virus evolves and in response to interventions.
Article
Biochemical Research Methods
David R. Stirling et al.
Summary: This study introduces CellProfiler 4, a new version of image analysis software with improved user interface and expanded functionality based on user feedback. Performance enhancements and optimizations have been made for large-scale analysis pipelines, providing researchers with significantly improved computational tools for extracting biological information effectively.
BMC BIOINFORMATICS
(2021)
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Article
Multidisciplinary Sciences
Medini K. Annavajhala et al.
Summary: The emergence of the B.1.526 lineage of SARS-CoV-2, with mutations such as E484K, has led to its rapid dominance in New York City. This variant is resistant to therapeutic monoclonal antibodies and less susceptible to neutralization by antibodies from recovered or vaccinated individuals, contributing to its fast spread.
Article
Microbiology
Agnieszka M. Szemiel et al.
Summary: This study selected drug-resistant SARS-CoV-2 populations with decreased sensitivity to remdesivir (RDV) in vitro, identifying a mutation in NSP12 that decreases RDV sensitivity. There is no evidence of widespread transmission of RDV-resistant mutants among globally circulating SARS-CoV-2 variants. Additionally, emerging SARS-CoV-2 variants showed substitutions at Spike sites corresponding to those identified in vitro, indicating their potential to arise without immune selection.
Review
Microbiology
Philip V'kovski et al.
Summary: This review discusses key aspects of coronavirus biology and their implications for SARS-CoV-2 infections, treatment, and prevention strategies. Understanding virus-host interactions at the molecular level is crucial for developing effective intervention strategies. Summarizing the discoveries of SARS-CoV-2 infection and comparing it with other coronaviruses will support future preparedness and combat strategies.
NATURE REVIEWS MICROBIOLOGY
(2021)
Article
Biochemical Research Methods
Pauli Virtanen et al.
Article
Microbiology
Xuping Xie et al.
CELL HOST & MICROBE
(2020)
Article
Medicine, General & Internal
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Multidisciplinary Sciences
Lihong Liu et al.
Article
Chemistry, Medicinal
Robert L. Hoffman et al.
JOURNAL OF MEDICINAL CHEMISTRY
(2020)
Article
Microbiology
Chengjin Ye et al.
Article
Microbiology
Agnes P. Chan et al.
Article
Biochemical Research Methods
Nikki E. Freed et al.
BIOLOGY METHODS & PROTOCOLS
(2020)
Editorial Material
Infectious Diseases
Yuelong Shu et al.
Article
Virology
Xiaoyu Xue et al.
JOURNAL OF VIROLOGY
(2008)
Article
Chemistry, Medicinal
Syaulan Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY
(2006)
